Cosmos Health Secures 5.2M-Unit Target Pharma Deal, Orderbook Jumps 31% to 32.7M
COSM sits 68% above its 52-week low of $0.162 on light trading volume (0.1× avg).
Summary
Cana Laboratories signed five-year contract manufacturing agreements with Target Pharma for 5.2 million units, lifting the orderbook to over 32.7 million units — a 31% jump since June. The deals cover mupirocin and tretin, adding anti-infective and dermatology categories. This follows the ROSARTIA agreement with Viofar on September 11, bringing September additions to 7.7 million units. The company says the orderbook has nearly tripled since the start of the year, converting its $5.5 million facility investment into contracted recurring production. Management targets over $10 million in annual profit at full capacity.
At the time of this announcement, COSM was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.